Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven S Carroll

Showing results (21-30 of 38) with videos related to

Pageof 4
Sort By:
Journal of the American Chemical Society|March 15, 2008
Molecular modeling based approach to potent P2-P4 macrocyclic inhibitors of hepatitis C NS3/4A proteaseNigel J Liverton, M Katharine Holloway, John A McCauley, et al.
Journal of Medicinal Chemistry|April 16, 2004
Structure-activity relationship of purine ribonucleosides for inhibition of hepatitis C virus RNA-dependent RNA polymeraseAnne B Eldrup, Charles R Allerson, C Frank Bennett, et al.
Journal of Medicinal Chemistry|December 4, 2003
Synthesis and evaluation of imidazole acetic acid inhibitors of activated thrombin-activatable fibrinolysis inhibitor as novel antithromboticsJames C Barrow, Philippe G Nantermet, Shaun R Stauffer, et al.
Antimicrobial Agents and Chemotherapy|September 25, 2004
A 7-deaza-adenosine analog is a potent and selective inhibitor of hepatitis C virus replication with excellent pharmacokinetic propertiesDavid B Olsen, Anne B Eldrup, Linda Bartholomew, et al.
The Journal of Biological Chemistry|September 11, 2003
Characterization of resistance to non-obligate chain-terminating ribonucleoside analogs that inhibit hepatitis C virus replication in vitroGiovanni Migliaccio, Joanne E Tomassini, Steven S Carroll, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of MK-1220: A Macrocyclic Inhibitor of Hepatitis C Virus NS3/4A Protease with Improved Preclinical Plasma ExposureMichael T Rudd, John A McCauley, John W Butcher, et al.
Antimicrobial Agents and Chemotherapy|May 23, 2012
MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variantsVincenzo Summa, Steven W Ludmerer, John A McCauley, et al.
Journal of Medicinal Chemistry|February 19, 2010
Discovery of vaniprevir (MK-7009), a macrocyclic hepatitis C virus NS3/4a protease inhibitorJohn A McCauley, Charles J McIntyre, Michael T Rudd, et al.
Journal of Medicinal Chemistry|October 1, 2004
Structure-activity relationship of heterobase-modified 2'-C-methyl ribonucleosides as inhibitors of hepatitis C virus RNA replicationAnne B Eldrup, Marija Prhavc, Jennifer Brooks, et al.
Science Translational Medicine|February 22, 2023
Potent targeted activator of cell kill molecules eliminate cells expressing HIV-1Carl J Balibar, Daniel J Klein, Beata Zamlynny, et al.
Pageof 4

Showing results (21-30 of 38) with videos related to

Sort By:
Pageof 4
Journal of the American Chemical Society|March 15, 2008
Molecular modeling based approach to potent P2-P4 macrocyclic inhibitors of hepatitis C NS3/4A proteaseNigel J Liverton, M Katharine Holloway, John A McCauley, et al.
Journal of Medicinal Chemistry|April 16, 2004
Structure-activity relationship of purine ribonucleosides for inhibition of hepatitis C virus RNA-dependent RNA polymeraseAnne B Eldrup, Charles R Allerson, C Frank Bennett, et al.
Journal of Medicinal Chemistry|December 4, 2003
Synthesis and evaluation of imidazole acetic acid inhibitors of activated thrombin-activatable fibrinolysis inhibitor as novel antithromboticsJames C Barrow, Philippe G Nantermet, Shaun R Stauffer, et al.
Antimicrobial Agents and Chemotherapy|September 25, 2004
A 7-deaza-adenosine analog is a potent and selective inhibitor of hepatitis C virus replication with excellent pharmacokinetic propertiesDavid B Olsen, Anne B Eldrup, Linda Bartholomew, et al.
The Journal of Biological Chemistry|September 11, 2003
Characterization of resistance to non-obligate chain-terminating ribonucleoside analogs that inhibit hepatitis C virus replication in vitroGiovanni Migliaccio, Joanne E Tomassini, Steven S Carroll, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of MK-1220: A Macrocyclic Inhibitor of Hepatitis C Virus NS3/4A Protease with Improved Preclinical Plasma ExposureMichael T Rudd, John A McCauley, John W Butcher, et al.
Antimicrobial Agents and Chemotherapy|May 23, 2012
MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variantsVincenzo Summa, Steven W Ludmerer, John A McCauley, et al.
Journal of Medicinal Chemistry|February 19, 2010
Discovery of vaniprevir (MK-7009), a macrocyclic hepatitis C virus NS3/4a protease inhibitorJohn A McCauley, Charles J McIntyre, Michael T Rudd, et al.
Journal of Medicinal Chemistry|October 1, 2004
Structure-activity relationship of heterobase-modified 2'-C-methyl ribonucleosides as inhibitors of hepatitis C virus RNA replicationAnne B Eldrup, Marija Prhavc, Jennifer Brooks, et al.
Science Translational Medicine|February 22, 2023
Potent targeted activator of cell kill molecules eliminate cells expressing HIV-1Carl J Balibar, Daniel J Klein, Beata Zamlynny, et al.
Pageof 4